Index -
P/E -
EPS (ttm) -8.23
Insider Own 51.28%
Shs Outstand 19.38M
Perf Week -23.35%
Market Cap 46.84M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 10.71M
Perf Month -27.02%
Income -154.29M
PEG -
EPS next Q -
Inst Own 11.30%
Short Float 6.34%
Perf Quarter -28.73%
Sales 33.52M
P/S 1.40
EPS this Y -
Inst Trans 4.62%
Short Ratio 41.98
Perf Half Y -36.95%
Book/sh 1.43
P/B 1.49
EPS next Y -
ROA -60.96%
Short Interest 0.68M
Perf Year -5.04%
Cash/sh 0.09
P/C 24.65
EPS next 5Y -
ROE -165.13%
52W Range 1.59 - 7.97
Perf YTD -13.86%
Dividend Est. -
P/FCF -
EPS past 5Y -718.48%
ROI -268.29%
52W High -73.26%
Beta 0.44
Dividend TTM -
Quick Ratio 0.29
Sales past 5Y 12.07%
Gross Margin 26.10%
52W Low 34.03%
ATR (14) 0.27
Dividend Ex-Date -
Current Ratio 0.35
EPS Y/Y TTM -748.86%
Oper. Margin -162.19%
RSI (14) 33.22
Volatility 16.59% 10.54%
Employees 120
Debt/Eq 2.11
Sales Y/Y TTM 109.81%
Profit Margin -460.34%
Recom 1.00
Target Price 25.00
Option/Short Yes / Yes
LT Debt/Eq 0.84
EPS Q/Q 75.08%
Payout -
Rel Volume 3.30
Prev Close 2.14
Sales Surprise -42.97%
EPS Surprise -70.83%
Sales Q/Q 273.09%
Earnings -
Avg Volume 16.18K
Price 2.13
SMA20 -18.27%
SMA50 -23.52%
SMA200 -38.06%
Trades
Volume 8,397
Change -0.63%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-23 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$5 → $1
Dec-22-22 Downgrade
Oppenheimer
Outperform → Perform
Jun-22-22 Initiated
H.C. Wainwright
Buy
$15
Apr-06-22 Downgrade
Truist
Buy → Hold
$10
Jan-28-22 Initiated
Oppenheimer
Outperform
$9
Nov-24-21 Initiated
Morgan Stanley
Equal-Weight
$9
Today 08:30AM
Oct-22-24 08:30AM
Oct-18-24 06:00PM
Oct-16-24 05:15PM
Sep-05-24 04:05PM
04:45PM
Loading…
Aug-28-24 04:45PM
Aug-23-24 05:00PM
Jul-31-24 08:30AM
Jun-03-24 08:38AM
May-24-24 05:15PM
May-14-24 09:15AM
Apr-22-24 08:00AM
Apr-19-24 05:30PM
Apr-18-24 04:30PM
Apr-15-24 08:00AM
09:00AM
Loading…
Apr-08-24 09:00AM
Mar-26-24 09:00AM
Mar-20-24 09:15AM
Mar-14-24 09:15AM
Mar-12-24 09:20AM
Mar-07-24 09:35AM
Feb-23-24 04:10PM
(GlobeNewswire) +7.13%
-9.56%
Feb-14-24 04:05PM
Feb-01-24 09:00AM
Jan-25-24 09:00AM
Jan-18-24 01:40PM
Jan-04-24 01:00PM
Jan-03-24 07:30PM
12:00PM
Nov-24-23 01:15PM
09:00AM
Loading…
Oct-18-23 09:00AM
Sep-07-23 04:10PM
Aug-29-23 09:00AM
Jul-27-23 09:07AM
09:00AM
Jul-18-23 09:00AM
Jun-29-23 04:05PM
Jun-01-23 09:15AM
May-23-23 10:56AM
May-19-23 04:21PM
May-10-23 09:00AM
May-01-23 04:01PM
Apr-27-23 09:00AM
Apr-12-23 09:00AM
Apr-05-23 09:00AM
Apr-04-23 09:00AM
Apr-03-23 09:00AM
Mar-28-23 10:55AM
09:00AM
Feb-02-23 07:53AM
Feb-01-23 04:05PM
Jan-26-23 04:17PM
Jan-11-23 01:35PM
01:22PM
Jan-06-23 08:10AM
Jan-04-23 04:10PM
Dec-05-22 08:00AM
Nov-30-22 09:55AM
Nov-10-22 05:00PM
04:10PM
09:10AM
Oct-06-22 08:00AM
Oct-03-22 08:00AM
Sep-27-22 08:00AM
Sep-26-22 08:00AM
Sep-15-22 02:29PM
Sep-06-22 04:10PM
Aug-09-22 04:10PM
Jul-27-22 08:00AM
Jul-04-22 10:08AM
Jun-08-22 04:10PM
Jun-03-22 08:00AM
May-18-22 08:30AM
May-16-22 04:10PM
(GlobeNewswire) -12.53%
+17.76%
Mar-31-22 04:05PM
Mar-15-22 04:05PM
12:59PM
Feb-15-22 04:05PM
(GlobeNewswire) +8.36%
+8.39%
Jan-27-22 05:38PM
(GuruFocus.com) -6.47%
+9.23%
05:38PM
Jan-18-22 08:00AM
Dec-27-21 08:00AM
Dec-15-21 09:04AM
Dec-13-21 08:00AM
Nov-29-21 08:00AM
Nov-16-21 05:35AM
Nov-15-21 08:00AM
Nov-12-21 04:05PM
Sep-20-21 08:00AM
08:00AM
Aug-16-21 05:15PM
(GlobeNewswire) -5.38%
+11.38%
Aug-04-21 07:00PM
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lim Kok Thay 10% Owner Jan 12 '24 Buy 0.25 21,410,983 5,331,335 51,473,762 Jan 17 05:22 PM
Index -
P/E -
EPS (ttm) -1.02
Insider Own 39.41%
Shs Outstand 191.79M
Perf Week 5.76%
Market Cap 176.47M
Forward P/E -
EPS next Y -0.39
Insider Trans 0.45%
Shs Float 116.21M
Perf Month 12.03%
Income -118.89M
PEG -
EPS next Q -0.14
Inst Own 20.92%
Short Float 9.53%
Perf Quarter -45.88%
Sales 50.83M
P/S 3.47
EPS this Y 46.09%
Inst Trans 38.70%
Short Ratio 9.54
Perf Half Y 8.25%
Book/sh -1.77
P/B -
EPS next Y 43.00%
ROA -102.93%
Short Interest 11.08M
Perf Year -46.19%
Cash/sh 0.04
P/C 25.61
EPS next 5Y -
ROE -
52W Range 0.73 - 2.63
Perf YTD -54.90%
Dividend Est. -
P/FCF 14.48
EPS past 5Y -
ROI -
52W High -65.02%
Beta 1.17
Dividend TTM -
Quick Ratio 0.19
Sales past 5Y 14.78%
Gross Margin 60.16%
52W Low 25.77%
ATR (14) 0.11
Dividend Ex-Date -
Current Ratio 0.20
EPS Y/Y TTM -62.41%
Oper. Margin -195.02%
RSI (14) 48.38
Volatility 18.77% 12.08%
Employees 105
Debt/Eq -
Sales Y/Y TTM 119.45%
Profit Margin -233.88%
Recom 1.00
Target Price 9.88
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q -67.40%
Payout -
Rel Volume 1.16
Prev Close 0.97
Sales Surprise 5.94%
EPS Surprise -53.73%
Sales Q/Q 30.11%
Earnings Aug 28
Avg Volume 1.16M
Price 0.92
SMA20 3.58%
SMA50 -9.16%
SMA200 -31.79%
Trades
Volume 211,684
Change -5.18%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-16-24 Initiated
Alliance Global Partners
Buy
$14
Jun-13-24 Initiated
Rodman & Renshaw
Buy
$13
Oct-16-23 Initiated
B. Riley Securities
Buy
$4
Oct-13-23 Initiated
B. Riley Securities
Buy
$4
Oct-09-23 Initiated
H.C. Wainwright
Buy
$12
Oct-16-24 07:00AM
04:00AM
Oct-08-24 01:58PM
11:50AM
Oct-07-24 10:00AM
09:52AM
Loading…
09:52AM
Sep-26-24 09:00AM
Sep-18-24 09:00AM
Sep-12-24 09:00AM
Sep-09-24 09:00AM
Sep-05-24 09:00AM
Sep-03-24 09:00AM
09:00AM
Aug-30-24 09:00AM
Aug-29-24 09:00AM
09:00AM
Loading…
Aug-21-24 09:00AM
Aug-09-24 09:00AM
Aug-01-24 09:00AM
Jul-24-24 10:52AM
Jul-23-24 09:00AM
Jul-17-24 09:00AM
Jul-03-24 07:21AM
Jul-02-24 05:15PM
09:00AM
Jul-01-24 09:00AM
Jun-20-24 09:00AM
Jun-14-24 01:41PM
Jun-13-24 09:00AM
Jun-11-24 07:20PM
(GlobeNewswire) +18.75%
+8.27%
09:00AM
11:49AM
Loading…
Jun-10-24 11:49AM
Jun-06-24 02:56PM
May-30-24 01:19PM
May-24-24 01:40PM
09:00AM
May-14-24 09:00AM
08:53AM
May-13-24 09:00AM
Apr-25-24 04:01PM
Apr-24-24 08:00AM
Apr-16-24 09:00AM
Apr-09-24 09:00AM
Mar-27-24 09:00AM
Mar-21-24 09:30AM
Mar-20-24 11:00AM
09:00AM
Mar-19-24 09:00AM
Mar-18-24 09:00AM
Mar-15-24 02:45PM
09:00AM
Mar-05-24 04:01PM
09:00AM
Mar-04-24 09:00AM
Mar-02-24 03:25PM
Feb-29-24 05:32PM
(GlobeNewswire) -6.20%
-41.19%
Feb-28-24 09:00AM
Feb-27-24 09:00AM
Feb-26-24 04:53PM
09:00AM
Feb-20-24 09:00AM
Jan-08-24 09:00AM
Jan-02-24 09:00AM
Dec-26-23 11:00AM
Dec-20-23 09:00AM
Dec-19-23 09:00AM
Dec-15-23 09:00AM
Dec-12-23 09:00AM
Dec-06-23 09:00AM
Dec-04-23 09:00AM
09:00AM
Dec-01-23 09:00AM
Nov-30-23 09:00AM
Nov-28-23 09:00AM
Nov-27-23 09:00AM
Nov-22-23 09:00AM
Nov-21-23 09:00AM
Nov-17-23 09:00AM
Nov-15-23 09:00AM
Nov-02-23 09:00AM
09:00AM
Nov-01-23 09:00AM
Oct-27-23 03:38PM
02:05PM
Oct-26-23 06:12AM
Oct-09-23 02:55PM
Oct-07-23 07:27PM
Oct-04-23 12:59PM
Oct-03-23 09:00AM
Sep-27-23 09:00AM
Sep-25-23 09:00AM
Sep-22-23 11:38AM
Sep-21-23 04:05PM
Sep-14-23 09:00AM
Sep-13-23 09:00AM
Sep-12-23 05:34PM
09:00AM
09:00AM
Sep-11-23 09:00AM
Jul-27-23 09:00AM
Jul-21-23 05:53PM
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Followwill Dorman Director Oct 18 '24 Buy 0.99 1,000 990 2,300 Oct 18 04:29 PM Chun Jay Director Oct 18 '24 Buy 0.95 5,000 4,750 112,500 Oct 18 04:29 PM Wu Yue Alexander Director Oct 17 '24 Buy 0.95 20,000 18,992 25,000 Oct 18 09:14 AM Lemus David Director Oct 17 '24 Buy 0.90 2,000 1,800 2,000 Oct 18 09:10 AM Ji Henry Executive Chairperson Oct 17 '24 Buy 0.97 10,000 9,710 60,070 Oct 18 09:08 AM SHAH JAISIM See Remarks Oct 16 '24 Buy 0.99 30,000 29,751 77,333 Oct 17 12:44 PM Ma Stephen Hoi Chief Financial Officer Oct 16 '24 Buy 0.97 6,700 6,499 22,840 Oct 17 11:09 AM Followwill Dorman Director Jun 26 '24 Option Exercise 1.37 1,000 1,370 1,300 Jun 26 09:31 PM Wu Yue Alexander Director Jun 20 '24 Option Exercise 1.41 5,000 7,050 5,000 Jun 20 06:07 PM Ma Stephen Hoi Chief Financial Officer Jun 20 '24 Option Exercise 1.41 2,000 2,820 16,140 Jun 20 04:54 PM Chun Jay Director Jun 20 '24 Option Exercise 1.41 5,000 7,050 107,500 Jun 20 04:49 PM SHAH JAISIM See Remarks Jun 20 '24 Option Exercise 1.73 14,000 24,220 47,333 Jun 20 04:43 PM Ji Henry Executive Chairperson Jun 18 '24 Option Exercise 1.41 6,000 8,460 311,273 Jun 18 09:26 PM SHAH JAISIM See Remarks Jun 14 '24 Option Exercise 1.41 33,333 47,000 33,333 Jun 14 04:02 PM Ji Henry Executive Chairperson May 17 '24 Buy 0.88 50,000 43,985 50,070 May 17 06:42 PM Chun Jay Director May 17 '24 Buy 0.90 57,500 51,641 102,500 May 17 06:41 PM SHAH JAISIM See Remarks May 16 '24 Buy 0.84 83,061 69,846 98,943 May 17 05:36 PM SHAH JAISIM See Remarks May 17 '24 Buy 0.92 56,939 52,099 155,882 May 17 05:36 PM Ma Stephen Hoi Chief Financial Officer May 17 '24 Buy 0.88 14,140 12,443 14,140 May 17 04:29 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite